Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) appointed Glenn Reicin as chief financial officer, effective immediately, the company announced. The pharmaceutical company also reiterated its 2026 net product revenue guidance of $1.0 to $1.04 billion.

Reicin brings experience from both publicly traded and privately held biopharmaceutical companies. He most recently served as chief financial officer at Eccogene, where he built the company's financial infrastructure for potential initial public offering readiness. Previously, he held CFO and COO positions at Alladapt Immunotherapeutics, overseeing fundraising and clinical operations.

Earlier in his career, Reicin worked as a research analyst at Morgan Stanley for 15 years and spent four years as managing director at Skyline Ventures. In his new role at Harmony, he will oversee the finance organization, including financial planning, accounting, treasury, investor relations, and risk management.

"Glenn's experience leading organizations through periods of growth and transformation will be instrumental as we look to execute on our strategy," said Jeffrey M. Dayno, president and CEO of Harmony Biosciences.

The appointment follows the departure of Sandip Kapadia from the CFO position. Dayno thanked Kapadia for his contributions during his tenure with the company.

Harmony Biosciences develops and commercializes therapies for patients with rare neurological diseases. The Plymouth Meeting, Pennsylvania-based company was established by Paragon Biosciences LLC in 2017.